Can pemetinib extend life?

According to publicly released information, pemetinib has demonstrated significant efficacy in the treatment of cholangiocarcinoma patients with FGFR2 gene fusions or rearrangements. In the FIGHT-202 (NCT02924376) clinical trial, pemetinib monotherapy achieved an overall response rate of NCT02924376 pan>36%, including 2.8% of complete responses and 33% of partial responses. This data clearly shows that pemetinib has a significant therapeutic effect on patients with cholangiocarcinoma with specific genetic mutations.

More importantly, pemetinib not only performed well in response rate, but also achieved impressive results in extending survival. The drug's median overall survival (OS) reached 21.1 months. In comparison, the historical average survival time of patients treated with second- and third-line treatments in the past was only 6-7 months. This means that the pemetinib regimen more than tripled patients' survival. This data undoubtedly brings new hope to patients with cholangiocarcinoma.

In addition to extending overall response rate and survival, pemetinib also performed well in terms of disease control rate and duration of response. In clinical trials, the disease control rate of pemetinib reached 82%, which means that the disease of most patients was effectively controlled. At the same time, the median duration of response was 9.1 months, and 63% of patients achieved remission for 6 months or longer, further demonstrating the durable efficacy of pemetinib.

While evaluating the efficacy of a drug, we cannot ignore its safety and tolerability. According to clinical trial data, most of the adverse reactions of pemetinib are grade 1 or grade 2, and there are no uncontrollable adverse reactions. This suggests that patients were able to maintain a relatively good quality of life while receiving pemetinib.